ClinicalTrials.gg
RecruitingNCT06730347Updated Jun 2, 2026

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

A Phase 2 interventional study of Lorigerlimab in Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by MacroGenics. Recruiting at 16 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by MacroGenics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 287 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
246th of 591
80 · median 60
Started
2025
with 54 others
Phase 2
178 of 715
35 open now
Primary completion
2027-07
later than 129 of 286 live
Registered
614th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 246th largest by planned enrollment of the 591 interventional ones that give a count, is one of 55 that started in 2025, is one of 178 in phase 2, reaches primary completion later than 129 of the 286 other live ones, and was the 614th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC.

Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends.

Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.

03

Conditions studied

  • Platinum-resistant Ovarian Cancer
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Clear Cell Adenocarcinoma of Ovary
  • Clear Cell Adenocarcinoma of Vulva
  • Clear Cell Adenocarcinoma of Vagina
  • Clear Cell Adenocarcinoma of Cervix
  • Clear Cell Adenocarcinoma of Uterus
  • Clear Cell Adenocarcinoma of Fallopian Tube
  • Clear Cell Adenocarcinoma of Peritoneum
  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed high-grade serous epithelial ovarian cancer, including primary peritoneal, or fallopian tube cancer, resistant to platinum based chemotherapy. OR
  • Histologically confirmed clear cell carcinoma of the ovary (including primary peritoneal and fallopian tube), endometrium, vagina, vulva, or cervix.
  • Persistent or recurrent disease with documented disease progression.
  • Participants with PROC must have received at least 1 but not more than 3 for PROC.
  • Participants with CCGC must have received at least 1 prior line of therapy for CCGC.
  • Participants with a known breast cancer (BRCA) mutation (germline or somatic) must have received a Poly ADP-ribose polymerase (PARP) inhibitor, if locally approved and available, and experienced disease progression or intolerance on the PARP inhibitor.
  • Participants must have at least one lesion that meets the definition of by v1.1.
  • Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue, or be willing to undergo a procedure to obtain a fresh tumor sample.
  • Participants have acceptable physical condition and laboratory values.
  • Participants of must agree to use highly effective methods of .
  • Participants must not be pregnant, planning to be pregnant, or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Primary platinum- disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum- containing chemotherapy.
  • Prior treatment with a (e.g., anti-PD-1/PD-L1, anti-PD-L2, anti-CTLA-4). Prior use of immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) is allowed for clear cell endometrial and clear cell cervical cancer.
  • Active or .
  • Prior stem cell, tissue, or solid organ transplant.
  • Paracentesis (removal of fluid from the abdomen) within 4 weeks prior to initiation of study treatment.
  • Another hematologic or solid tumor ≥ stage 1 that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 3 years from first dose of study treatment. Participants with another tumor that has a negligible risk for or death such as, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast are eligible.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort A (PROC) high dose

    Lorigerlimab 6 mg/kg IV every 21 days

    Biological: Lorigerlimab

  • Experimental
    Cohort A (PROC) low dose

    Lorigerlimab 3 mg/kg IV every 21 days

    Biological: Lorigerlimab

  • Experimental
    Cohort B (CCGC)

    Lorigerlimab 6 mg/kg IV every 21 days

    Biological: Lorigerlimab

  • Experimental
    Cohort C (CCGC)

    Lorigerlimab 3 mg/kg IV every 21 days

    Biological: Lorigerlimab

Interventions

  • BiologicalLorigerlimab

    Bispecific DART protein binding PD-1 and CTLA-4

    Also known as: MGD019

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator

    The ORR, is defined as the percentage of patients in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST, version 1.1 criteria. CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.

    Time frame: Throughout the study up to approximately 2 years

Secondary outcomes

  1. Frequency and severity of adverse events (AEs), serious AEs (SAEs), immune-related AEs (irAEs), and AEs leading to dose modifications or treatment discontinuation.

    Time frame: Throughout the study, up to approximately 2 years

  2. Median duration of response (DoR) per RECIST 1.1 criteria

    The DoR will be calculated per RECIST v1.1 criteria, as determined by the investigator, from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.

    Time frame: Throughout the study, up to approximately 2.5 years

  3. Median progression free survival (PFS) per RECIST 1.1 criteria

    PFS is defined as the time from the first dose of study treatment to the date of documented PD or death from any cause, whichever occurs first.

    Time frame: Throughout the study, up to 2.5 years

  4. Percent change from baseline in tumor size

    Tumor size is defined as the sum of diameters of the target lesions.

    Time frame: Throughout the study, up to 2.5 years

  5. Best percent change from baseline in tumor size

    Tumor size is defined as the sum of diameters of the target lesions.

    Time frame: Throughout the study, up to 2.5 years

  6. Disease control rate (DCR)

    DCR, per RECIST v1.1 criteria, as determined by the investigator, is defined as the proportion of participants in the response evaluable population who achieve a CR, PR or stable disease for at least 3 months.

    Time frame: Throughout the study, up to 2.5 years

07

Study locations

16 of 16 sites recruiting
  • UCLA
    Los Angeles, California 90095, United States
    Recruiting
    • Surya Nagesh · Contact
    • Salani Ritu, MD · Principal investigator
  • Ochsner MD Anderson Cancer Center
    New Orleans, Louisiana 70115, United States
    Recruiting
    • Chad Hamilton · Contact
    • Chad Hamilton, MD · Principal investigator
  • START Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Judy Phan · Contact
    • Manish Sharma, MD · Principal investigator
  • West Penn Allegheny Health
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Sarah Crafton · Contact
    • Sarah Crafton, MD · Principal investigator
  • The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center
    Houston, Texas 77030, United States
    Recruiting
    • Mariana Gallardo · Contact
    • Amir Jazaeri, MD · Principal investigator
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Alison Procter · Contact
    • Drew Rasco, MD · Principal investigator
  • Wisconsin Institute Medical Research- UW Cancer Connect
    Madison, Wisconsin 53705, United States
    Recruiting
    • Claire Kostechka · Contact
    • Janelle Sobecki, MD · Principal investigator
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Stephanie Lheureux · Contact
    • Stephanie Lheureux, MD · Principal investigator
  • McGill University
    Montreal, Quebec H4A3J1, Canada
    Recruiting
    • Phuong Nam Natalie Nguyen · Contact
    • Lucy Gilbert, MD · Principal investigator
  • National Cancer Center
    Goyang-si, Gyeonggi-do 410-763, South Korea
    Recruiting
    • Myong Cheol Lim · Contact
    • Myong Cheol Lim, MD · Principal investigator
  • Seoul National University Hospital Bundang Hospital
    Seongnam-si, Gyeonnggi-Do 463-707, South Korea
    Recruiting
    • Yong Beom Kim · Contact
    • Yong Beom Kim, MD · Principal investigator
  • Yonsei University Health System Severance Hospital
    Seoul, 03722, South Korea
    Recruiting
    • Yujeong Huh · Contact
    • Jung Yun Lee, MD · Principal investigator
  • Gangnam Severance Hospital
    Seoul, 06273, South Korea
    Recruiting
    • Mina Jang · Contact
    • Jae-Hoon Kim, MD · Principal investigator
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
    Recruiting
    • Jin Hwa Hong · Contact
    • Jin Hwa Hong, MD · Principal investigator
  • Seoul National University Hospital
    Seoul, 110-74, South Korea
    Recruiting
    • Jae-Weon Kim · Contact
    • Jae-Weon Kim, MD · Principal investigator
  • Samsung Medical Center
    Seoul, 135-710, South Korea
    Recruiting
    • Jeong-Won Lee · Contact
    • Jeong-Won Lee, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
May 1, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06730347
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
May 1, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

Global Trial Manager
Contact
info@macrogenics.com
301-251-5172
Pepi Pencheva
study director · MacroGenics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorigerlimab

Start the discussion